Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NAMS Stock Forecast 2025-2026
$18.37
Current Price
$2.06B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NAMS Price Targets
+185.1%
To High Target of $52.37
+133.2%
To Median Target of $42.84
+99.3%
To Low Target of $36.62
NAMS Price Momentum
-9.2%
1 Week Change
+21.5%
1 Month Change
-14.3%
1 Year Change
-28.5%
Year-to-Date Change
-32.7%
From 52W High of $27.29
+30.7%
From 52W Low of $14.06
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching NewAmsterdam Pharma (NAMS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NAMS and similar high-potential opportunities.
Latest NAMS Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, NAMS has a bullish consensus with a median price target of $42.84 (ranging from $36.62 to $52.37). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $18.37, the median forecast implies a 133.2% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NAMS Analyst Ratings
9
Buy
0
Hold
0
Sell
NAMS Price Target Range
Low
$36.62
Average
$42.84
High
$52.37
Current: $18.37
Latest NAMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NAMS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2025 | Needham | Serge Belanger | Buy | Maintains | $40.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $42.00 |
| Feb 27, 2025 | Needham | Serge Belanger | Buy | Maintains | $42.00 |
| Feb 27, 2025 | Scotiabank | George Farmer | Sector Outperform | Maintains | $52.00 |
| Jan 28, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $40.00 |
| Jan 24, 2025 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $40.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $48.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Initiates | $48.00 |
| Dec 11, 2024 | Scotiabank | George Farmer | Sector Outperform | Maintains | $47.00 |
| Dec 5, 2024 | Needham | Serge Belanger | Buy | Reiterates | $36.00 |
| Nov 21, 2024 | Needham | Serge Belanger | Buy | Reiterates | $36.00 |
| Nov 11, 2024 | Needham | Serge Belanger | Buy | Reiterates | $36.00 |
| Nov 7, 2024 | Needham | Serge Belanger | Buy | Reiterates | $36.00 |
| Sep 23, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Reiterates | $37.00 |
| Sep 5, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $31.00 |
| Aug 28, 2024 | Needham | Serge Belanger | Buy | Initiates | $36.00 |
| Jul 30, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $31.00 |
| Jun 7, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $31.00 |
| May 15, 2024 | TD Cowen | Tyler Van Buren | Buy | Initiates | $0.00 |
| Mar 14, 2024 | Scotiabank | George Farmer | Sector Outperform | Initiates | $35.00 |
NewAmsterdam Pharma Co. N.V. (NAMS) Competitors
The following stocks are similar to NewAmsterdam Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NAMS
NewAmsterdam Pharma
mkt cap
2.06B
NewAmsterdam Pharma Co. N.V. (NAMS) Financial Data
NewAmsterdam Pharma Co. N.V. has a market capitalization of $2.06B with a P/E ratio of -7.2x. The company generates $45.56M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +1,490.5% quarter-over-quarter, while maintaining an operating margin of -338.5% and return on equity of -46.2%.
Valuation Metrics
Market Cap
$2.06B
Enterprise Value
$1.24B
P/E Ratio
-7.2x
PEG Ratio
-9.7x
Price/Sales
45.3x
Growth & Margins
Revenue Growth (YoY)
+1,490.5%
Gross Margin
N/A
Operating Margin
-338.5%
Net Margin
0.0%
EPS Growth
+1,490.5%
Financial Health
Cash/Price Ratio
+41.4%
Current Ratio
8.1x
Debt/Equity
0.1x
ROE
-46.2%
ROA
-18.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
NewAmsterdam Pharma Co. N.V. (NAMS) Business Model
About NewAmsterdam Pharma Co. N.V.
What They Do
Develops therapies for cardiovascular diseases.
Business Model
The company operates within the life sciences sector, focusing on research, development, and commercialization of innovative cardiovascular therapies. It generates revenue through the successful launch of new medications that address critical healthcare needs and improve patient outcomes.
Additional Information
NewAmsterdam Pharma is committed to addressing unmet medical needs in the cardiovascular space, which is a significant area of concern for global health. The company's innovative approach has implications for both the healthcare sector and the economy, highlighting the importance of ongoing advancements in medical treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Dr. Michael Harvey Davidson FACC, Facp., M.D.
Country
Netherlands
IPO Year
2022
Website
www.newamsterdampharma.comNewAmsterdam Pharma Co. N.V. (NAMS) Latest News & Analysis
Latest News
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
4 days ago
Quick Summary
NewAmsterdam Pharma expects EMA submission in 2H25. PREVAIL Phase 3 CVOT is on track. Company reported $808.5 million in cash as of March 31, 2025. R&D day scheduled for June 11, 2025.
Why It Matters
The announcement of EMA submission and positive trial results boosts confidence in NewAmsterdam Pharma's potential, signaling future revenue growth and financial stability, which can attract investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma reported a quarterly loss of $0.49 per share, exceeding the Zacks Consensus Estimate of a loss of $0.45.
Why It Matters
NewAmsterdam Pharma's larger-than-expected quarterly loss suggests weaker performance, potentially impacting investor confidence and stock price negatively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Data from BROADWAY and TANDEM studies were presented at EAS 2025 and published in The New England Journal of Medicine and The Lancet, indicating significant developments in their respective research areas.
Why It Matters
New clinical data from BROADWAY and TANDEM could impact stock prices of related biotech firms, influencing investor sentiment and potential market movements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma granted 197,000 share options to eleven new non-executive hires as part of its 2024 Inducement Plan, aiding recruitment efforts in its CVD-focused drug development.
Why It Matters
The approval of share options for new hires indicates NewAmsterdam's growth strategy and potential for innovation in cardiovascular treatments, which may impact future stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
New data from BROADWAY and TANDEM Phase 3 trials show obicetrapib's positive effects on key lipid and lipoprotein biomarkers.
Why It Matters
Positive Phase 3 trial results for obicetrapib may indicate potential market approval, impacting the stock value of the company and related sectors in pharmaceuticals and biotechnology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma (Nasdaq: NAMS) will have CFO Ian Somaiya participate in a virtual fireside chat at the Needham Virtual Healthcare Conference on April 7, 2025, at 12:45 p.m. ET.
Why It Matters
NewAmsterdam's participation in the healthcare conference highlights its potential developments in cardiovascular treatments, attracting investor interest in its innovative pipeline and financial outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NAMS Stock
What is NewAmsterdam Pharma Co. N.V.'s (NAMS) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, NewAmsterdam Pharma Co. N.V. (NAMS) has a median price target of $42.84. The highest price target is $52.37 and the lowest is $36.62.
Is NAMS stock a good investment in 2025?
According to current analyst ratings, NAMS has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NAMS stock?
Wall Street analysts predict NAMS stock could reach $42.84 in the next 12 months. This represents a 133.2% increase from the current price of $18.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NewAmsterdam Pharma Co. N.V.'s business model?
The company operates within the life sciences sector, focusing on research, development, and commercialization of innovative cardiovascular therapies. It generates revenue through the successful launch of new medications that address critical healthcare needs and improve patient outcomes.
What is the highest forecasted price for NAMS NewAmsterdam Pharma Co. N.V.?
The highest price target for NAMS is $52.37 from at , which represents a 185.1% increase from the current price of $18.37.
What is the lowest forecasted price for NAMS NewAmsterdam Pharma Co. N.V.?
The lowest price target for NAMS is $36.62 from at , which represents a 99.3% increase from the current price of $18.37.
What is the overall NAMS consensus from analysts for NewAmsterdam Pharma Co. N.V.?
The overall analyst consensus for NAMS is bullish. Out of 13 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $42.84.
How accurate are NAMS stock price projections?
Stock price projections, including those for NewAmsterdam Pharma Co. N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 9:57 AM UTC